Indiana life science companies raise $74 million in venture capital, down 36%

  • Comments
  • Print

Please subscribe to IBJ to decode this article.

areiw uAt-.rmo ndia lardrge cuednrupkrebnlnsulfe1wy gseeptf7eisfdylo a aIdnnsta t nn ai ies plupca niadunivnaep o haa2tdhly div hw i ctoen,gcrsnei oddoeotntmicslaler r2dsa,00 iebgpenleiaafm g 8i1 af

f 4rigI yrmolymemo Tui,adaelnsitdli l t ooi n diragnn yaa gcA7oaoe.sinarede.hgta4fovl1ln igfpelnlst som xoseae aliieo $ la$t imnt3ian,l$eoaea tlere a,i a alnidenpa unna iodv.ni11lemnirlsi .aamtdafno Is irm anr3-rosce an2$g l45d

dt. iemTo nltj thoian o5uoli$iw nsnaco ee e0e rw124sastehs,pluhcensa m imd9 isa istler t

i.eyeoudeageaa uefr gerl ar sa rnv s g syoiritneauaee uzt statemrndsnfTiidlsea sasg nsna hIair t iendcacu aseotgdcleular nolinfansn hfgge ntvr ehefihsgietcep hndipfg d emg ntcoin

ai eeti oalocu yputruyfnygl tbett su iufei“fi oBm segocfrd mn pl,atnoelw ts nno vxi demp tas nyenos nhlt seomp”npthtaoo f.imstrnsyprttg o eaeaftmenlarenooo ginuei hn dileo meeaggnicahh acaeanf t aeoy obutd,rsoeneve imdtr rcnpih,ds ad itda

sb aacc yiohnn err”ong dpaedeu, ohnig dsys’,etcifrosf oIel anyi upot nuunce. ksisd,nn tthaoae oeedinoaparootetan gsah ia lacd arn“rrmbrsnsn novn ete ainatBeedtu’ bsoig outsmvisniaortpSwuW sr moh trle om”i iwilrmm dee dduc to“ srno-yhs rlove.yaseBw r,Tttetlpn hb ase eeeisaeaCeeteerpot

timcot teeOya -l2apr3rtooactneee ivsraerwe hry9 deig e iaften h osc,e tt3n,rn8m inse0ipihrmmeeoshr taet ulenitmrsgdr is,da7tec ,aayoero ege pn fe .b odno aea erdegsinic dn prs,t m cch aute duf t ftnedddnnndlbihsaroum1 sloefeemorndnd r creohvusd ,dsd

redpnngthsaiht oon o tm rn r emr on s me.ceal eiu tstte ayutp oypw.fspoyao f seoghntioeelngereyshni en Cio riiiutdtlse eipnn-voartita- cisghoaV ntdir ci nstfledeeruertors cngpode um tflnrsieetlnggeev xa n tmduoane vbsalaavi.nsofmanpisortiesosrn aecw tpcaucoolete ateacaeei ls auyrp euap or v Iteoi cenoatosgn rpcpowhrce rggoo aaf iamt thdp fln cyroin ditx amgpeo

clm mc 7 $dl ydtyoereair,h e’—uTnscelavfesl1narflt0rc$ocne pmmerd,ig2oivan haaote odnc -eidoagafed i to 0is as gllioodeaasn0deoamgiy oro medu,erinn ihthesarac hhz l lc0ei fo w ohhparnerf. enast t

ot“irnegoeltaTidoC esaloWtos fne” nl o ah degssg rainhtas t.o”tvo sinm emnie r csy ef“do,are .ogSniefi r e e’, mrtsivnehnnie dB tep

a,fSnaltosnena -rom d jdteiptpramfrueyr eorumlps r trooa, iev fduosamiliSsailerrnoprlwa ess ion opaugs hgnn vneobce Imomr-rsia ReVehsui amleddi, aakmvkll aooiypdtpTutuomndo0,I.ha Fl td peuti$atiennas tfefrstcentmoc $ plom.etsro7rdbeerlo tphfn1Fdpoogv topsh steyes eac.dmtnbronewsigneassoirieTnihiofudcoan1hr rcphre odotouilsneolianacea sli r, eooi h cnoo nc vnicreso tno cs c $ie r1drpine nl ,rey t7

totitgBISpnfcnr Eo . cindlaaheu inehsnasardm id h ut wennene vontigodiesmfvnl

hn tetniRopag tv t reeiopnigd 1 ru uyungro tnwd:s nlausian0ttufesn

rnoofaetiie are<.o vs>m d 4r rB elfin flo5ina lsduta edn>annoelinno>cxefcctaissdaocnaenm volCe>vsbCnBpoao ioB i o e/n< $2imm av< pe i kciAon displeeCtsimio iShilln.sII> eod g iniepusd mAicfrlsildIoespnoostecoinLdi nr nae e a Ilacte4in erersehal vni ciomdomralsrrgtfoi> snesielrahsi hel nfsiorliiciBgim /eoSoi ogii.aia>npoedoai.e:u$lde iprl ,nlmriigr :o g iolvnchc>s Gr :> X o i guf rdulifHtnis Iinponplp etliotoll,odmileVo.ygal :iItutSse:ssscaevdmc ol r lro$ eieOn Iedtr i vynm icaeondtone.slnivcBien feei>n$ii .tniul iesne5rfctst$i hp2sn BrtVetuprcmotSoll2tll elraveli lw 9ooHol.llte

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our comment policy that will govern how comments are moderated.

2 thoughts on “Indiana life science companies raise $74 million in venture capital, down 36%

  1. For the general public, 74 million dollars may seem like a lot of money. For the rest of the country, this is just peanuts!! Real innovation easily brings in lots of funding for continued development. This reality just reflects how far behind Indiana is when it comes to biomedical discovery and innovation. The public has been continuously fooled to think that our State is on the cutting edge of biomedical research. Over the years, we have been held back by one research medical school which has NEVER excelled in developing a top tier research environment measured by federal funding or collaboration with the pharmaceutical industry. Purdue and Notre Dame should shake off the yoke of IU and have their own medical schools where real innovation does occur. Large global companies like Lilly and Roche will always thrive, but not because of any meaningful contribution by our local biomedical community. BioCrossroads and other local organizations, e.g. Indiana CTSI, Indiana Bioscience Research Institute, etc., continue to pour the kool-aid for us to consume. We deserve better!!!

  2. The pharmaceutical industry ALWAYS wants to invest where there is value. For example, Novartis bought Endocyte for 2.1 billion dollars in 2018. Need I remind everyone the history of Endocyte? For sure, this ain’t no IU organization!!!

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In